Overview A type of bone growth disorder. Due to genetic mutations, the cartilage does not convert into a bone during fetal ...

Longer follow-up results from a mid-stage trial indicate the company’s treatment for a genetic cause of dwarfism may be competitive to an approved therapy from BioMarin Pharmaceutical.

BridgeBio touted longer-term data for its achondroplasia drug infigratinib from a mid-stage trial on Tuesday, setting the ...

BridgeBio reported top-line data from the midphase PROPEL 2 trial in March 2023 and followed up with six-month data around one year ago. Tuesday, the biotech unwrapped 12- and 18-month data that add ...

BridgeBio reversed premarket gains and tumbled midday Tuesday after the drugmaker's growth disorder treatment topped Wall Street's expectations in a Phase 2 study.Please watch the video at ...

7 Little Johnston's Trent and Amber on 'Fear' of Daughter Elizabeth Giving Birth with Achondroplasia (Exclusive) TLC "The biggest challenge would be adjusting to an average-sized granddaughter because ...

BridgeBio announced Tuesday that its drug candidate infigratinib showed positive Phase II results in treating children with achondroplasia, the most common form of dwarfism, and may have an edge over ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. Today, FDA advisers are convening to discuss Lykos ...

As Liz's family members gather to learn the size of her and Brice's baby, her father Trent admits that he'd prefer if his ...